<?xml version='1.0' encoding='UTF-8' standalone='no'?>
<rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:bqbiol="http://biomodels.net/biology-qualifiers/" xmlns:collex="http://www.collex.org/schema#" xmlns:bqmodel="http://biomodels.net/model-qualifiers/" xmlns:scoro="http://purl.org/spar/scoro/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:biomodel="http://biomodels.net/model-qualifiers/">
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <dc:title>Grange, Holford, Guentert, 2001</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <prism:keyword>L-dopa</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <prism:keyword>metabolism</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <prism:keyword>PKPD</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <prism:keyword>benserazide</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <dc:description>

#### Model Status



 This CellML model runs in PCenv, COR and OpenCell to recreate the published results (Figure 6). This model is simulates the administration of L-dopa only, without benserazide added. This model was created using the paper equations supplemented by suggestions made by Dr. Holford, as the original code was not available. 
 


#### Model Structure



PURPOSE: To study the PK interaction of L-dopa/benserazide in rats. METHODS: Male rats received a single oral dose of 80 mg/kg L-dopa or 20 mg/kg benserazide or 80/20 mg/kg L-dopa/benserazide. Based on plasma concentrations the kinetics of L-dopa, 3-O-methyldopa (3-OMD), benserazide, and its metabolite Ro 04-5127 were characterized by noncompartmental analysis and a compartmental model where total L-dopa clearance was the sum of the clearances mediated by amino-acid-decarboxylase (AADC), catechol-O-methyltransferase and other enzymes. In the model Ro 04-5127 inhibited competitively the L-dopa clearance by AADC. RESULTS: The coadministration of L-dopa/benserazide resulted in a major increase in systemic exposure to L-dopa and 3-OMD and a decrease in L-dopa clearance. The compartmental model allowed an adequate description of the observed L-dopa and 3-OMD concentrations in the absence and presence of benserazide. It had an advantage over noncompartmental analysis because it could describe the temporal change of inhibition and recovery of AADC. CONCLUSIONS: Our study is the first investigation where the kinetics of benserazide and Ro 04-5127 have been described by a compartmental model. The L-dopa/benserazide model allowed a mechanism-based view of the L-dopa/benserazide interaction and supports the hypothesis that Ro 04-5127 is the primary active metabolite of benserazide.






The original paper reference is cited below:




A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats, Susan Grange, Nicholas H. G. Holford, Theodor W. Guentert, 2001, *Pharm Res.*, volume 18, 1174-1184. [PubMed ID: 11587490](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=11587490 &amp;query_hl=1&amp;itool=pubmed_docsum) 





|  |
| --- |
|  |
| Schematic diagram of the conceptual model to describe kinetics of L-dopa and 3-OMD. |



</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <collex:thumbnail rdf:resource="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex/grange_2001a.png">http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex/grange_2001a.png</collex:thumbnail>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <rdfs:label>Susan Grange</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <foaf:name>Susan Grange</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <dc:creator rdf:resource="local:00001">local:00001</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00002">
    <rdfs:label>Nicholas H. G. Holford</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00002">
    <foaf:name>Nicholas H. G. Holford</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <dc:creator rdf:resource="local:00002">local:00002</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00003">
    <rdfs:label>Theodor W. Guentert</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00003">
    <foaf:name>Theodor W. Guentert</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <dc:creator rdf:resource="local:00003">local:00003</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00004">
    <dc:identifier rdf:resource="http://identifiers.org/orcid:0000-0001-5801-5510">http://identifiers.org/orcid:0000-0001-5801-5510</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00004">
    <rdfs:label>Bilal Shaikh</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00004">
    <foaf:accountName rdf:resource="https://orcid.org/0000-0001-5801-5510">https://orcid.org/0000-0001-5801-5510</foaf:accountName>
  </rdf:Description>
  <rdf:Description rdf:about="local:00004">
    <foaf:name>Bilal Shaikh</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <dc:contributor rdf:resource="local:00004">local:00004</dc:contributor>
  </rdf:Description>
  <rdf:Description rdf:about="local:00005">
    <rdfs:label>Geoffrey Nunns</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00005">
    <foaf:name>Geoffrey Nunns</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <dc:contributor rdf:resource="local:00005">local:00005</dc:contributor>
  </rdf:Description>
  <rdf:Description rdf:about="local:00006">
    <dc:identifier rdf:resource="https://identifiers.org/pmr:32d3dcc3ab074d17905c10f2ba26b54f">https://identifiers.org/pmr:32d3dcc3ab074d17905c10f2ba26b54f</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00006">
    <rdfs:label>PMR: 32d3dcc3ab074d17905c10f2ba26b54f</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <bqmodel:is rdf:resource="local:00006">local:00006</bqmodel:is>
  </rdf:Description>
  <rdf:Description rdf:about="local:00007">
    <dc:identifier rdf:resource="https://identifiers.org/doi/10.1023/a:1010935228654">https://identifiers.org/doi/10.1023/a:1010935228654</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00007">
    <rdfs:label>Susan Grange, Nicholas H. G. Holford &amp; Theodor W. Guentert. A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats. Pharmaceutical Research 18, 8: 1174-1184 (2001).</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <bqmodel:isDescribedBy rdf:resource="local:00007">local:00007</bqmodel:isDescribedBy>
  </rdf:Description>
  <rdf:Description rdf:about="local:00008">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00008">
    <rdfs:label>CC BY 3.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex">
    <dc:license rdf:resource="local:00008">local:00008</dc:license>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex/grange_2001_bens.cellml">
    <dc:title>A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats (L-dopa + Benserazide)</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex/grange_2001_bens.cellml">
    <dc:description>

#### Model Status



 This CellML model runs in PCenv, COR and OpenCell to recreate the published results (Figures 5 and 7). This model describes the metabolism of both L-dopa and benserazide. This model was created using the paper equations supplemented by suggestions made by Dr. Holford, as the original code was not available. 
 


#### Model Structure



PURPOSE: To study the PK interaction of L-dopa/benserazide in rats. METHODS: Male rats received a single oral dose of 80 mg/kg L-dopa or 20 mg/kg benserazide or 80/20 mg/kg L-dopa/benserazide. Based on plasma concentrations the kinetics of L-dopa, 3-O-methyldopa (3-OMD), benserazide, and its metabolite Ro 04-5127 were characterized by noncompartmental analysis and a compartmental model where total L-dopa clearance was the sum of the clearances mediated by amino-acid-decarboxylase (AADC), catechol-O-methyltransferase and other enzymes. In the model Ro 04-5127 inhibited competitively the L-dopa clearance by AADC. RESULTS: The coadministration of L-dopa/benserazide resulted in a major increase in systemic exposure to L-dopa and 3-OMD and a decrease in L-dopa clearance. The compartmental model allowed an adequate description of the observed L-dopa and 3-OMD concentrations in the absence and presence of benserazide. It had an advantage over noncompartmental analysis because it could describe the temporal change of inhibition and recovery of AADC. CONCLUSIONS: Our study is the first investigation where the kinetics of benserazide and Ro 04-5127 have been described by a compartmental model. The L-dopa/benserazide model allowed a mechanism-based view of the L-dopa/benserazide interaction and supports the hypothesis that Ro 04-5127 is the primary active metabolite of benserazide.






The original paper reference is cited below:




A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats, Susan Grange, Nicholas H. G. Holford, Theodor W. Guentert, 2001, *Pharm Res.*, volume 18, 1174-1184. [PubMed ID: 11587490](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=11587490 &amp;query_hl=1&amp;itool=pubmed_docsum) 





|  |
| --- |
|  |
| Schematic diagram of the conceptual model to describe kinetics of benserazide and Ro 04-5127. |




</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex/grange_2001_bens.cellml">
    <collex:thumbnail rdf:resource="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex/grange_2001b.png">http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex/grange_2001b.png</collex:thumbnail>
  </rdf:Description>
  <rdf:Description rdf:about="local:00009">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00009">
    <rdfs:label>CC BY 3.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex/grange_2001_bens.cellml">
    <dc:license rdf:resource="local:00009">local:00009</dc:license>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex/grange_2001.cellml">
    <dc:title>A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats (L-dopa)</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex/grange_2001.cellml">
    <dc:description>

#### Model Status



 This CellML model runs in PCenv, COR and OpenCell to recreate the published results (Figure 6). This model is simulates the administration of L-dopa only, without benserazide added. This model was created using the paper equations supplemented by suggestions made by Dr. Holford, as the original code was not available. 
 


#### Model Structure



PURPOSE: To study the PK interaction of L-dopa/benserazide in rats. METHODS: Male rats received a single oral dose of 80 mg/kg L-dopa or 20 mg/kg benserazide or 80/20 mg/kg L-dopa/benserazide. Based on plasma concentrations the kinetics of L-dopa, 3-O-methyldopa (3-OMD), benserazide, and its metabolite Ro 04-5127 were characterized by noncompartmental analysis and a compartmental model where total L-dopa clearance was the sum of the clearances mediated by amino-acid-decarboxylase (AADC), catechol-O-methyltransferase and other enzymes. In the model Ro 04-5127 inhibited competitively the L-dopa clearance by AADC. RESULTS: The coadministration of L-dopa/benserazide resulted in a major increase in systemic exposure to L-dopa and 3-OMD and a decrease in L-dopa clearance. The compartmental model allowed an adequate description of the observed L-dopa and 3-OMD concentrations in the absence and presence of benserazide. It had an advantage over noncompartmental analysis because it could describe the temporal change of inhibition and recovery of AADC. CONCLUSIONS: Our study is the first investigation where the kinetics of benserazide and Ro 04-5127 have been described by a compartmental model. The L-dopa/benserazide model allowed a mechanism-based view of the L-dopa/benserazide interaction and supports the hypothesis that Ro 04-5127 is the primary active metabolite of benserazide.






The original paper reference is cited below:




A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats, Susan Grange, Nicholas H. G. Holford, Theodor W. Guentert, 2001, *Pharm Res.*, volume 18, 1174-1184. [PubMed ID: 11587490](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=11587490 &amp;query_hl=1&amp;itool=pubmed_docsum) 





|  |
| --- |
|  |
| Schematic diagram of the conceptual model to describe kinetics of L-dopa and 3-OMD. |




</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex/grange_2001.cellml">
    <collex:thumbnail rdf:resource="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex/grange_2001a.png">http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex/grange_2001a.png</collex:thumbnail>
  </rdf:Description>
  <rdf:Description rdf:about="local:00010">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00010">
    <rdfs:label>CC BY 3.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/32d3dcc3ab074d17905c10f2ba26b54f.omex/grange_2001.cellml">
    <dc:license rdf:resource="local:00010">local:00010</dc:license>
  </rdf:Description>
</rdf:RDF>
